SEC EDGARSEP 121 min read$HALO

Torley Helen sold $6.4M of HALO

Torley Helen (PRESIDENT AND CEO) sold 60,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $107.28 ($107.01–$108.67, $6.44M total) across 7 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Torley Helen

Published Sep 12, 2026, 12:35 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 12, 2026, 1:01 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HALO

Bearish

medium confidence

Mentioned

$HALO

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HALOBearishLow

Why it matters

The disclosed sale reduces insider ownership, which some investors view as a bearish indicator, though the pre‑arranged plan tempers speculation.

Market read

Insider sell of $6.4M by the CEO is a material event for HALO shareholders and may influence short‑term price action.

What to watch

No concurrent earnings or clinical data releases; the sale may simply be portfolio rebalancing.

Relevance 5/10Novelty 6/10Timing: filed after market close on 2026‑09‑11

Background

Form 4 filing discloses insider transactions required by SEC; provides transparent insight into insider holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HALOBearishMedium confidence

Context

CEO Helen Torley sold 60,000 shares for $6.4M via a 10b5‑1 plan, reducing her stake to 767,780 shares.

Expected impact

Possible modest downside of 2‑4% over the next few days.

Evidence & confidence

CEO insider sales are material; $6.4M is sizable for a mid‑cap biotech, but no accompanying news suggests a strategic shift.

Market effects

Sector

May raise scrutiny on biotech insider activity but limited sector impact.

Regional

US biotech investors may adjust short positions.

Global

Minimal global effect; confined to Halozyme shareholders.

Counterpoint

What could challenge this read

The sale could be routine liquidity planning under a 10b5‑1, not a negative signal.

Key entities

person
Helen Torley
President and CEO of Halozyme Therapeutics, insider seller.
company
Halozyme Therapeutics, Inc.
Biotech company developing enzyme‑based therapies, ticker HALO.

Read at source ← All news

SEP 16

$HALOHighAI 8/10

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics (HALO) plans to offer $1.05B in convertible senior notes due 2033, with an option for $150M more. Proceeds will fund capped call transactions, repurchase existing notes, and general corporate purposes. The notes are convertible under certain conditions and will accrue interest semi-annually.

prnewswire.com2 min

SEP 12

$HALOMed

Record Revenue Growth Boosts Halozyme Shares

Halozyme (HALO) reported record Q2 2026 revenue of $481M, up 48% YOY, and raised full-year guidance. Shares have risen 59% YTD, supported by strong institutional buying and robust fundamentals, including 3-year sales and EPS growth of 28.5% and 28%, respectively.

yahoo.com2 min

SEP 10

$VRTXMed

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Myriad Genetics (MYGN) reported Q2 revenues of $190.7M, down 10.5% YoY, missing estimates. Its stock fell 40.7% to $3.19. Halozyme Therapeutics (HALO) reported $481M in revenues, up 47.7% YoY, beating estimates. Its stock rose 24.5% to $106.74. Amgen (AMGN) reported $10.05B in revenues, up 9.5% YoY, exceeding expectations. Its stock is flat at $391.29. The market has seen shifts in leadership due to AI and geopolitical concerns.

finance.yahoo.com3 min

AUG 21

$HALOMedAI 8/10

HALO Stock Rises 36% in a Month: Here's What You Should Know

Halozyme Therapeutics (HALO) stock rose 36.4% in the past month due to strong Q2 2026 results and raised full-year guidance. The company's ENHANZE drug-delivery technology, licensed to partners like J&J and Roche, drove revenue growth. Royalty revenues increased 46.7% YoY to $373.8M, and total revenues are now projected at $1.84-$1.91B for 2026.

tradingview.com2 min

AUG 20

$BMRNMedAI 8/10

Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.